Limited Effect of CpG ODN in Preventing Type 1 Diabetes in NOD Mice
2
조회
0
다운로드
0
인용
0
참고문헌
초록
Abstract
Type 1 diabetes is considered as Th1 cell mediated autoimmune disease and the suppression of Th1 cells or the activation of Th2 cells has been regarded as a plausible immunologic intervention for the prevention of type 1 diabetogenesis in a rodent model. CpG ODN is an immunostimulatory sequence primarily present in bacterial DNA, viral DNA and BCG. CpG ODN is conventionally classified as a Th1 cell activator, which has been clinically applied to cancer, allergy and infectious disease. Recently, there was a promising report of that CpG ODN administration suppressed the development of type 1 diabetes in NOD mice by inducing Th2 cell mediated cytokine. However, the antidiabetogenic effect of CpG ODN on NOD mice is controversial. Thus, two studies were serially undertaken with various kinds of CpG motif to find a more optimal sequence and administration method. In the first study, CpG ODN was vaccinated four times and pancreatic inflammation and the quantity of serum insulin subsequently evaluated. In the second study, the amounts of IFN γ and IL-4 in sera were measured as representative cytokines of Th1 and Th2 cells, respectively. As a result, vaccination or continuous injection of CpG ODN failed to show a preventive effect on type 1 diabetogenesis in NOD mice. Structural differences of CpG ODN also had no affect on the result. CpG ODN also consistently showed affect on the pancreatic pathology. The productions of IFN γ and IL-4 were detected only in the K and D type CpG ODN administration groups. Comparison of the two cytokines leads to the conclusion that CpG ODN generated a Th1-weighted response in both study groups. It was assumed that CpG ODN failed to produce Th2-weighted cytokine milieu, which can overcome the genetically determined phenotype of NOD mice. Given these results, it was concluded that the immunotherapeutic application of CpG ODN on Type 1 diabetes had clear limitations.
참고문헌 (26)
- "Diabetes mellitus", 19, pp.79~107 (2002)
- "Improving outcomes for young people with diabetes use of new technology and skills- based training approach is urgently needed", 18, pp.861~3 (2001)
- "Insulin-dependent diabetes mellitus as an autoimmune disease", pp.516~42
- "Th1 and Th2 CD4+ T cells in the pathogenesis of organ-specific autoimmune disease", 16, pp.34~8 (1995)
- "Insulin dependent diabetes mellitus", 85, pp.291~7 (1996)
- "Therapeutic alteration of insulin-dependent diabetes mellitus progression by T cell tolerance to glutamic acid decarboxylase 65 peptides in vitro and in vivo", 167, pp.569~77 (2001)
- "Immunomodulatory therapy of human type 1 diabetes lessons from the mouse", 108, pp.31~3 (2001)
- "Immunologic "vaccination" for the prevention of autoimmune diabetes (type 1A).", 22, pp.7~15 (1999)
- "Th1 to Th2 cytokine shifts in nonobese diabetic mice: Sometimes an outcome, rather than the cause, of diabetes resistance elicited by immunostimulation", 166, pp.1352~9 (2001)
- "The NOD mouse model of type 1 diabetes As good as it gets", 5, pp.601~4 (1999)
- "The nonobese diabetic mouse as a model of autoimmune diabetes Immune dysregulation gets the NOD", 7, pp.727~38 (1997)
- "CpG motifs in bacterial DNA and their immune effects", 20, pp.709~60 (2002)
- "Immunoregulatory and cytokine imbalance in the pathogenesis of IDDM", pp.613~21
- "Vaccination against tuberculosis by DNA injection", 2, pp.888~92 (1996)
- "Immune effect and therapeutic applications of CpG motif in bacterial DNA", 48, pp.303~5 (2000)
- "Causing a commotion in the blood immunotherapy progresses from bacteria to bacterial DNA", 21, pp.521~6 (2000)
- "CpG oligodeoxynucleotides as vaccine adjuvant in primates", 168, pp.1659~63 (2002)
- "Human peripheral blood cells differentially recognize and respond to two distinct CpG motifs", 166, pp.2372~7 (2001)
- "Distinct CpG DNA and polyinosinic-polycytidylic acid double-stranded RNA, respectively, stimulate CD 11c-type II dendritic precursor and CD 11c+ dendritic cells to produce type I IFN.", 166, pp.2291~5 (2001)
- "Induction of interleukin-6 and interleukin-12 in bovine B lymphocytes, monocytes, and macrophages by a CpG oligonucleotide (ODN 2059) containing the GTC GTT motif.", 21, pp.871~81 (2001)
- "Comparison of the effect of different immunological adjuvants on the antibody and T-cell response to immunization with MVC1-KLH and GD3- KLH conjugate cancer vaccines", 18, pp.597~603 (1999)
- "CpG oligonucleotides enhances host defense during murine tuberculosis", 70, pp.147~52 (2002)
- "Vaccination with empty plasmid DNA or CpG oligonucleotide inhibits diabetes in nonobese diabetic mice Modulation of spontaneous 60-k Da heat shock protein autoimmunity", 165, pp.6148~55 (2000)
- "Prevention of insulitis by BCG administration in NOD mice of the neonatal period", 11, pp.97~105 (1998)
- "Prevention of overt diabetes and insulitis by BCG administration in the NOD mice in the breast-fed period", 33, pp.49~54 (2000)
- "How BCG led to the discovery of immunostimulatory DNA", 52, pp.1~11 (1999)